News
A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...
Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative to ...
Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound, is suing four telehealth companies for allegedly selling illegal copies of the drug made by compounding pharmacies.
Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.
Orforglibron, a pill form of GLP-1 weight loss injections like Ozempic and Mounjaro, is undergoing clinical trials. Drugmaker Eli Lilly said the first trial showed similar weight loss and ...
(Bloomberg) -- Eli Lilly & Co. shares surged after its experimental pill helped patients shed weight and control blood sugar about as well as Ozempic, an advance that could turbocharge what’s ...
That compares favorably with Novo's injected drug Ozempic, where diabetic patients on the highest dose lost roughly 6% of their body weight. Lilly said weight loss hadn’t plateaued at the ...
Illustration: Elizabeth Smelov The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals in a pivotal study, helping ...
A pill, which is normally easier to make than an injection, may also help Lilly with supply issues. Both Lilly and Novo struggled to produce enough of their weight-loss shots to meet market ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback